Drugs in Dev. Dermatology
Phase III
Spain 
Lead Product(s) : Lebrikizumab
Therapeutic Area : Dermatology
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
EBGLYSS® (lebrikizumab) Receives Positive CHMP Opinion for Moderate-to-severe Atopic Dermatitis
Details : Ebglyss (lebrikizumab) is an investigational, monoclonal antibody that binds IL-13, which is received positive CHMP opinion for moderate-to-severe atopic dermatitis.
Product Name : Ebglyss
Product Type : Antibody
Upfront Cash : Inapplicable
September 15, 2023
Lead Product(s) : Lebrikizumab
Therapeutic Area : Dermatology
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Lebrikizumab
Therapeutic Area : Dermatology
Study Phase : Phase III
Sponsor : Eli Lilly
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : In the initial 16-week placebo-controlled period of ADvocate 1 and ADvocate 2, the incidence of treatment-emergent adverse events (AEs) and serious AEs among patients treated with lebrikizumab was consistent with that of the previous Phase 2 lebrikizumab...
Product Name : Ebglyss
Product Type : Antibody
Upfront Cash : Inapplicable
August 16, 2021
Lead Product(s) : Lebrikizumab
Therapeutic Area : Dermatology
Highest Development Status : Phase III
Sponsor : Eli Lilly
Deal Size : Inapplicable
Deal Type : Inapplicable
Reset All
